Abstract:Neonatal sepsis is a major cause of morbidity and mortality. It is the third leading cause of neonatal mortality globally constituting 13% of overall neonatal mortality Despite the high burden of neonatal sepsis, high‐quality evidence in diagnosis and treatment is scarce. Due to the diagnostic challenges of sepsis and the relative immunosuppression of the newborn, many neonates receive antibiotics for suspected sepsis. Antibiotics have become the most used therapeutics in neonatal intensive care units, and observational studies in high‐income countries suggest that 83% to 94% of newborns treated with antibiotics for suspected sepsis have negative blood cultures. The last Cochrane Review was updated in 2005. There is a need for an updated systematic review assessing the effects of different antibiotic regimens for late‐onset neonatal sepsis. To assess the beneficial and harmful effects of different antibiotic regimens for late‐onset neonatal sepsis. We searched the following electronic databases: CENTRAL (2021, Issue 3); Ovid MEDLINE; Embase Ovid; CINAHL; LILACS; Science Citation Index EXPANDED and Conference Proceedings Citation Index – Science on 12 March 2021. We also searched clinical trials databases and the reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi‐RCTs. We included RCTs comparing different antibiotic regimens for late‐onset neonatal sepsis. We included participants older than 72 hours of life at randomisation, suspected or diagnosed with neonatal sepsis, meningitis, osteomyelitis, endocarditis, or necrotising enterocolitis. We excluded trials that assessed treatment of fungal infections. Three review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We used the GRADE approach to assess the certainty of evidence. Our primary outcome was all‐cause mortality, and our secondary outcomes were: serious adverse events, respiratory support, circulatory support, nephrotoxicity, neurological developmental impairment, necrotising enterocolitis, and ototoxicity. Our primary time point of interest was at maximum follow‐up. We included five RCTs (580 participants). All trials were at high risk of bias, and had very low‐certainty evidence. The five included trials assessed five different comparisons of antibiotics. We did not conduct a meta‐analysis due to lack of relevant data. Of the five included trials one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacillin plus amikacin with cefotaxime plus gentamicin; one trial compared meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin); and one trial compared vancomycin plus gentamicin with vancomycin plus aztreonam. None of the five comparisons found any evidence of a difference when assessing all‐cause mortality, serious adverse events, circulatory support, nephrotoxicity, neurological developmental impairment, or necrotising enterocolitis; however, none of the trials were near an information size that could contribute significantly to the evidence of the comparative benefits and risks of any particular antibiotic regimen. None of the trials assessed respiratory support or ototoxicity. The benefits and harms of different antibiotic regimens remain unclear due to the lack of well‐powered trials and the high risk of systematic errors. Current evidence is insufficient to support any antibiotic regimen being superior to another. RCTs assessing different antibiotic regimens in late‐onset neonatal sepsis with low risks of bias are warranted. Review question We reviewed the available evidence on different antibiotic regimens for newborns (from 72 hours of life to one month of life) with late‐onset sepsis. Background Sepsis in newborns is a severe and potential lethal condition, caused by the body's response to an infection. Neonatal sepsis is the third leading cause of neonatal death globally Despite this high burden of sepsis in newborns, high‐quality evidence in diagnosis and treatment is scarce. This Cochrane Review was originally published in 2005. To identify the most appropriate antibiotic policies for neonatal sepsis, there is a need to base these policies on an updated well‐conducted review. Therefore, there is a need for such a review assessing the effects of different antibiotic regimens for late‐onset neonatal sepsis. Study characteristics The evidence is current to March 2021. We included five trials randomising 580 participants. The five trials compared five different antibiotic regimens. Key results We included five trials: one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacil -Abstract Truncated-

Shorter versus longer duration antibiotic regimens for treatment of suspected neonatal sepsis

Efficacy of short‐course antibiotics for culture‐positive neonatal sepsis: A systematic review and meta‐analysis

Efficacy and safety of short- vs. standard-course antibiotics for culture-negative neonatal sepsis: a systematic review and meta-analysis

Antibiotic regimens for late-onset neonatal sepsis.

Antibiotic regimens for early-onset neonatal sepsis.

Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis

1214. Short versus long antibiotic treatment duration for febrile urinary tract infection and acute pyelonephritis: A systematic review and meta-analysis

Oral antibiotics for neonatal infections: a systematic review and meta-analysis

Shorter Versus Longer Duration of Antibiotic Treatment for Community-Acquired Pneumonia in Children: A Systematic Review and Meta-Analysis

1148. Duration of Antibiotic Therapy in the Treatment of Bacterial Meningitis in Young Infants: A Systematic Review and Narrative Synthesis

Duration of perioperative antibiotic prophylaxis in neonatal surgery: Less is more

Efficacy of Antibiotic Regimens for Pneumonia in Young Infants Aged 0-59 Days: A Systematic Review

Gram-Negative Neonatal Sepsis in Low- and Middle- Income Countries: How Appropriate are the WHO Recommended Empirical Sepsis Antibiotic Regimens? A Systematic Review and Meta-Analysis

Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria

Probiotic effect in preterm neonates with sepsis - A systematic review protocol

Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial

Protocolized versus non-protocolized weaning for reducing the duration of invasive mechanical ventilation in newborn infants

Contemporary trends in global mortality of sepsis among young infants less than 90 days old: protocol for a systematic review and meta-analysis

Sedation protocols to reduce duration of mechanical ventilation in the ICU: a Cochrane Systematic Review

Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial

Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)